Clinical Trials Related to Mantle Cell Lymphoma

Related studies linked through entity extraction aliases.

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Status: COMPLETED
Phase: PHASE2

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Status: COMPLETED
Phase: PHASE2

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

Status: TERMINATED
Phase: PHASE2

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE2

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE2

Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma

Status: TERMINATED
Phase: PHASE2

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE2

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE1/PHASE2

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Status: COMPLETED
Phase: PHASE3

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Status: TERMINATED
Phase: PHASE1

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Status: COMPLETED
Phase: PHASE2